Synergistic effects of a combined @entity3045 - @entity1854 regimen in XXXX and severe @entity1002 .

@entity1 @entity998 @entity3045 @entity1854 @entity583 @entity1455 @entity1002
The haemodynamic effects of a simultaneous infusion of @entity3045 and @entity1854 were measured in 20 @entity1 with @entity583 and severe @entity1002 . Six @entity1 also had clinical manifestations of @entity1455 . Ten @entity1 received @entity3045 first with the subsequent addition of @entity1854 ; in the other 10 @entity1 @entity1854 was infused first. @entity3045 was infused at a constant rate of 20 micrograms/min in all @entity1 , while the dose of @entity1854 , which averaged 51.25 micrograms/min, was adjusted to reduce left ventricular filling pressure (measured as pulmonary artery end-diastolic pressure) to approximately 15 mm Hg with reference to sternal angle. Cardiac index increased in all @entity1 from a mean of 1.8 to 2.6 l/min/m2 while pulmonary artery end-diastolic pressure fell significantly from 24 to 16 mm Hg. The adverse effects were small in most @entity1 : heart rate did not increase significantly and systolic arterial pressure fell on average from 112 to 96 mm Hg. Ten of the 20 @entity1 survived to leave hospital. @entity1854 accounted for most of the fall in filling pressure irrespective of treatment sequence, whereas both drugs contributed to the @entity998 . The haemodynamic benefits of this combined regimen were considerably greater than those achieved by either drug alone. Thus @entity3045 and @entity1854 have synergistic effects which influence favourably the two principal manifestations of @entity1002 after extensive @entity583 .
